<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01406249</url>
  </required_header>
  <id_info>
    <org_study_id>ECRIN-GC1107-XParTS II</org_study_id>
    <secondary_id>UMIN000006045</secondary_id>
    <nct_id>NCT01406249</nct_id>
  </id_info>
  <brief_title>XParTS II: Capecitabine/CDDP(XP) and S-1/CDDP(SP) as the First-line Treatment for Advanced Gastric Cancer</brief_title>
  <official_title>A Randomized Phase II Trial Comparing Capecitabine/CDDP(XP) and S-1/CDDP(SP) as the First-line Treatment for Advanced Gastric Cancer (XParTS II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epidemiological and Clinical Research Information Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Epidemiological and Clinical Research Information Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to elucidate the efficacy and safety of XP and SP for first-line
      treatment of Advanced Gastric Cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      XP and SP are either standard treatment for advanced gastric cancer. The aim of this study is
      to elucidate the efficacy and safety of Capecitabine/Cisplatin and S-1/Cisplatin for
      first-line treatment of Advanced Gastric Cancer.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival rate</measure>
    <time_frame>at 24weeks from patient enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-to treatment failure</measure>
    <time_frame>3year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>S-1,Cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Capecitabine, Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SP</intervention_name>
    <description>Drug: S-1:
S-1 will be administered at 40 mg/m2 orally, twice daily (80 mg/m2 total daily dose) on Days 1 through 21 of each 35-day treatment cycle.
Drug: Cisplatin:
Cisplatin will be administered at 60 mg/m2 by intravenous infusion on Day 8 of each 35-day treatment cycle.</description>
    <arm_group_label>S-1,Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XP</intervention_name>
    <description>Drug: Capecitabine:
Capecitabine will be administered at 1,000 mg/m2 orally, twice daily (2,000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.
Drug: Cisplatin:
Cisplatin will be administered at 80 mg/m2 by intravenous infusion on Day 1 of each 21-day treatment cycle.</description>
    <arm_group_label>Capecitabine, Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed gastric adenocarcinoma with unresectable metastatic or
             recurrent disease

          2. Lesions confirmed on imaging within 28 days before registration (not required
             measurable lesions as defined in RECIST version 1.1)

          3. No previous chemotherapy or radiotherapy. However, adjuvant chemotherapy is allowed
             the case of more than 6 months from the end of adjuvant chemotherapy

          4. ECOG Performance Status of 0 to 2

          5. Life expectancy of at least 3 months after registration

          6. Written informed consent

          7. Age of 20 to 74 years with either gender

          8. Adequate Major organ functions within 14 days before registration

        Exclusion Criteria:

          1. Positive HER2 status

          2. Previous history of fluoropyrimidines therapy within 6 months prior to registration

          3. Previous treatment with platinum agents

          4. Previous history of serious hypersensitivity to fluoropyrimidines or platinum agents

          5. Previous history of adverse reactions suggestive of dihydropyrimidine dehydrogenase
             (DPD) deficiency

          6. More than one cancer at the same time or more than one cancer at different times
             separated by a 5-year disease-free interval. However, multiple active cancers do not
             include carcinoma in situ or skin cancer which is determined to have been cured as a
             result of treatment.

          7. Obvious infection or inflammation (pyrexia ≥ 38.0˚C)

          8. Active hepatitis

          9. Heart disease that is serious or requires hospitalization, or history of such disease
             within past year

         10. Having complication that is serious or requires hospitalization (intestinal paralysis,
             intestinal obstruction, interstitial pneumonia or pulmonary fibrosis, poorly
             controlled diabetes mellitus, renal failure, liver disorders, or hepatic cirrhosis)

         11. Being treated or in need of treatment with flucytosine, phenytoin or warfarin
             potassium

         12. Chronic diarrhea (watery stool or ≥4 times/day)

         13. Active gastrointestinal bleeding

         14. Body cavity fluids requiring drainage or other treatment

         15. Clinical suspicion or previous history of metastasis to brain or meninges

         16. Women who are pregnant, breastfeeding, or potentially (hoping to become) pregnant

         17. Unwillingness to practice contraception

         18. Poor oral intake

         19. Psychiatric disorders which are being or may need to be treated with psychotropics

         20. Otherwise determined by investigators or site principal investigators to be unsuitable
             for participation in study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Akira Tsuburaya</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shonan Kamakura Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Epidemiological and Clinical Research Information Network</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8392</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2011</study_first_submitted>
  <study_first_submitted_qc>July 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2011</study_first_posted>
  <last_update_submitted>July 26, 2017</last_update_submitted>
  <last_update_submitted_qc>July 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unresectable gastric cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>StageIV gastric cancer</keyword>
  <keyword>adenocarcinoma of the stomach</keyword>
  <keyword>XP</keyword>
  <keyword>SP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

